Posted by Michael Wonder on 12 Mar 2024
Quizartinib approved to treat adult patients with a type of blood cancer
11 March 2024 - The MHRA has today approved quizartinib (Vanflyta) to be used alongside chemotherapy as first-line treatment for adults who have acute myeloid leukaemia.
Each year in the UK around 3,100 people are diagnosed with acute myeloid leukaemia, which can affect the different types of blood cells in the bone marrow, and can lead to bleeding, anaemia and infections.
